BACKGROUND: Multiple sclerosis (MS) is a chronic and debilitating disease of the central nervous system that affects approximately 570,000 persons in the United States and 2.3 million worldwide. As most individuals experience initial symptoms between the ages of 20 and 40 years, MS can have a significant impact on healthcare consumption, productivity and employment. OBJECTIVES: To compare the work productivity impairment in patients initiated on delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon β-1a/b or glatiramer acetate (ABCRE) therapies. METHODS: Data were identified from the Adelphi MS Disease Specific Programme, a cross-sectional study of MS patients in five EU countries and US. Relapsing Remitting MS (RRMS) patients were identified, receiving DMF or ABCRE therapies with treatment duration greater than 12 months. Inverse-probability-weighted regression-adjustment estimated average treatment effects (ATEs) across DMF and ABCRE cohorts, utilizing a propensity score generated from age, gender, EDSS score at current treatment initiation, BMI,  duration of current treatment, line of therapy, time since MS diagnosis, and number of comorbid conditions. Work productivity and daily activity impairment due to MS, as measured by the Work Productivity and Activity Impairment (WPAI:MS) questionnaire, were compared across treatment arms. RESULTS: Work productivity and activity impairment data was available for 160 and 243 patients, respectively. Overall work impairment due to MS was significantly lower in the DMF cohort (ATE=-13.92%, p<0.001, vs. 20.92%). Similarly, impairment while working (presenteeism) due to MS was significantly lower in the DMF cohort (ATE=-12.97%, p<0.001, vs. 19.45%).  No percent of work missed (absenteeism) was observed in the DMF cohort (ATE=-2.06%, p=0.012, vs. 2.06%). Daily activity impairment was significantly lower in the DMF cohort (ATE= -17.26%, p<0.001, vs. 25.31%). CONCLUSIONS: Compared with ABCRE patients, patients on DMF had a significantly lower work productivity loss as measured by WPAI-MS.